Search selective blockers of the zinc-dependent metalloproteinases 2nd and 9th type among the benzoylamino (phenylsulfonyl) amino-substituted cyclic aminoacids derivatives

The purpose of this study - search among the benzoylamino (phenyLsuLfonyL) amino-substituted cyclic aminoacids derivatives biologically active compounds exhibiting properties of the zinc-dependent metaLLproteinases 2nd and 9th type blockers which is known to pLay a key roLe in the pathogenesis of the myocardium earLy post-infarction remodeLing. In studying the effect of newLy synthesized compounds on metaLLoproteinase-9 LeveLs in bLood of rats with acute myocardiaL infarction were seLected compound Leader: 1-({4-[(4-chLorobenzoyL)amino]phenyL}suLfonyL-L-proLine, which effectiveLy bLocked the increase of this enzyme Level. Using echocardiography it was demonstrated that the seLected compound-Leader prevents the myocardiaL remodeLing deveLopment in the acute phase of experimentaL myocardiaL infarction, at Least not inferior to the reference inhibitor of metaLLoproteinases - doxycycLine.

металлопротеиназы 2-го и 9-го типа, постинфарктное ремоделирование миокарда, производные бензоила-мино(фенилсульфонил)-замещённых циклических аминокислот, metaLLproteinases 2nd- and 9th-type, post-infarction myocardiaL remodeLing, derivatives of the benzoyLamino (phenyLsuLfonyL) amino-substituted cycLic aminoacids

1. Гасанов А.Г., Бершова Т.В. Роль изменений внеклеточного матрикса при возникновении сердечно-сосудистых заболеваний. Биомед. химия. 2009; 55: 2: 155-168.

2. Крыжановский С.А., Колик Л.Г., Цорин И.Б., Ионова Е.О., Столярук В.Н., Сорокина А.В., Вититнова М.Б., Мирошкина И.А. Доказательство валидности эхокардиографии в модельных экспериментах на мелких животных. Бюл. эксп. биол. и медицины. 2016; 161: 3: 416-420.

3. Ali M.A., Fan X., Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc. Med. 2011; 21: 4: 112-118.

4. Bench T.J., Jeremias A., Brown D.L. Matrix metalloproteinase inhibiton with tetracyclines for the treatment of coronary artery disease. Pharmacol. Res. 2011; 64: 561-566.

5. Bencsik P., Paloczi J., Kocsis G.F., Pipis J., Belecz I., Varga Z.V., Csonka C., Görbe A., Csont T., Ferdinandy P. Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective. Pharmacol. Res. 2014; 80: 36-42.

6. Chang S.A., Chang H.J., Choi S.I., Chun E.J., Yoon Y.E., Kim H.K., Kim Y.J., Choi D.J., Sohn D.W., Helm R.H., Lardo A.C. Usefulness of left ventricular dyssynchrony after acute myocardial infarction, assessed by a tagging magnetic resonance image derived metric, as a determinant of ventricular remodeling. Am.J. Cardiol. 2009; 104: 1: 19-23.

7. Gallagher G.L., Jackson C.J., Hunyor S.N. Myocardial extracellular matrix remodeling in ischemic heart failure. Front. Biosci. 2007; 12: 1410-1419.

8. Griffin M.O., Fricovsky E., Ceballos G., Villarreal F. Tetracyclines: a pleotropic family of compounds with promising therapeutic properties. Review of the literature. Am.J. Physiol. Cell. Physiol. 2010; 299: 539-548.

9. Henderson K.K., Danzi S., Paul J. T., Leya G., Klein I., Samarel A.M. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ. Heart Fail. 2009; 2: 3: 243-252.

10. Hori M., Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 2009; 81: 3: 457-464.

11. Hughes B.G., Fan X., Cho W.J., Schulz. R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am.J. Physiol. Heart Circ. Physiol. 2014; 306: 5: H764-H770.

12. Hughes B.G., Schulz. R. Targeting MMP-2 to treat ischemic heart injury. Basic Res Cardiol 2014; 109(4):424.

13. Jugdutt B. J. The dog model of left ventricular remodeling after myocardial infarction. Card. Fail. 2002; 8: 6 Suppl: S472-S475.

14. Kandasamy A.D., Chow A.K., Ali M. A., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res. 2010; 85: 3: 413-423.

15. Lindsey M.L. Matrix Metalloproteinase-9 Post Myocardial Infarction: Breakdowns and Breakthroughs. Global J. Hum. Anat. Physiol. Res. 2014; 1: 6-9.

16. Moshal K.S., Rodriguez. W.E., Sen U., Tyagi S.C. Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. // Physiol. Res. - 2008. - Vol. 57, № 3. - P. 379-384.

17. Shamhart P.E., Meszaros J.G. Non-fibrillar collagens: key mediators of post-infarction cardiac remodeling? J. Mol. Cell. Cardiol. 2010; 48: 3: 530-537.

18. Spinale F. G. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol. Rev. 2007; 87: 1285-1342.

19. Tiyyagura S.R., Pinney S. P. Left ventricular remodeling after myocardial infarction: past, present, and future. Mt. Sinai J. Med. 2006; 73: 6: 840-851.

20. Zhou S.X., Zhou Y., Lei J., Zhang Y.L. Effects of oxidative stress on ventricular remodeling after myocardial infarction in rats. Nan Fang Yi Ke Da Xue Xue Bao. 2008; 28: 11: 2030-2034.